Literature DB >> 23031833

Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid.

Nasrin Asgari1, Reza Khorooshi, Søren T Lillevang, Trevor Owens.   

Abstract

The specificity and potential pathogenicity of autoantibodies vary between neurological diseases. It is often unclear whether their detection in cerebrospinal fluid (CSF) is a consequence or a cause of pathology. The goal was to test whether administration of brain-specific antibodies into CSF would be sufficient for pathology. Purified immunoglobulin G from a neuromyelitis optica patient was injected intrathecally with complement to naïve mice. Histopathological analysis at 7 days revealed damage to the ependyma, disruption of the CSF parenchymal barrier and pathologic lesions, distant from the site of injection. In the absence of complement there was no pathology. Autoantibody and complement in CSF are thus sufficient to initiate a pathologic cascade.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23031833     DOI: 10.1016/j.jneuroim.2012.09.010

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

1.  Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology.

Authors:  Daniel M Harrison; Jiwon Oh; Snehashis Roy; Emily T Wood; Anna Whetstone; Michaela A Seigo; Craig K Jones; Dzung Pham; Peter van Zijl; Daniel S Reich; Peter A Calabresi
Journal:  Mult Scler       Date:  2015-01-12       Impact factor: 6.312

2.  C5a/C5aR Pathway Plays a Vital Role in Brain Inflammatory Injury via Initiating Fgl-2 in Intracerebral Hemorrhage.

Authors:  Bangqing Yuan; Fenlan Fu; Shaokuan Huang; Chuangan Lin; Guang Yang; Kunlong Ma; Hui Shi; Zhao Yang
Journal:  Mol Neurobiol       Date:  2016-10-05       Impact factor: 5.590

3.  Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Xiaoming Yao; Tao Su; Alex J Smith; Alan S Verkman
Journal:  Acta Neuropathol       Date:  2017-05-31       Impact factor: 17.088

4.  Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.

Authors:  Hua Zhang; A S Verkman
Journal:  J Autoimmun       Date:  2014-03-31       Impact factor: 7.094

Review 5.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 6.  B cells in MS and NMO: pathogenesis and therapy.

Authors:  Markus Krumbholz; Edgar Meinl
Journal:  Semin Immunopathol       Date:  2014-05-16       Impact factor: 9.623

7.  Induction of endogenous Type I interferon within the central nervous system plays a protective role in experimental autoimmune encephalomyelitis.

Authors:  Reza Khorooshi; Marlene Thorsen Mørch; Thomas Hellesøe Holm; Carsten Tue Berg; Ruthe Truong Dieu; Dina Dræby; Shohreh Issazadeh-Navikas; Siegfried Weiss; Stefan Lienenklaus; Trevor Owens
Journal:  Acta Neuropathol       Date:  2015-04-14       Impact factor: 17.088

8.  Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study.

Authors:  Nasrin Asgari; Hanne Pernille Bro Skejoe; Soeren Thue Lillevang; Troels Steenstrup; Egon Stenager; Kirsten Ohm Kyvik
Journal:  BMC Neurol       Date:  2013-04-08       Impact factor: 2.474

9.  C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.

Authors:  Puay-Wah Phuan; Hua Zhang; Nithi Asavapanumas; Michael Leviten; Arnon Rosenthal; Lukmanee Tradtrantip; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-05-16       Impact factor: 15.887

Review 10.  Hypersensitivity Responses in the Central Nervous System.

Authors:  Reza Khorooshi; Nasrin Asgari; Marlene Thorsen Mørch; Carsten Tue Berg; Trevor Owens
Journal:  Front Immunol       Date:  2015-10-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.